Nuvation Bio Inc. (NUVB)
NYSE · Manufacturing · Pharmaceutical preparations
NUVB price, last 12 months
Key stats
- Previous close
- $5.73
- Open
- $5.73
- Day range
- $5.67 – $5.83
- 52-week range
- $2.99 – $9.75
- Volume
- 2.4M
- Avg volume (20 days)
- 4.7M
- Market cap
- $2.0B
Performance
Technicals and fundamentals
About Nuvation Bio Inc.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.
- Sector
- Manufacturing
- Industry
- Pharmaceutical preparations
- Listed on
- NYSE
- Market cap
- $2.0B